Journal of Translational Research

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +441518081136

Rapid Communication - Journal of Translational Research (2023) Volume 7, Issue 1

Symptoms of irritable bowel syndrome and ulcerative colitis in remission: A Feasibility Study.

Yiming Zhang*

Department of Pharmacology, Zunyi Medical University, Zhuhai, China

*Corresponding Author:
Yiming Zhang
Department of Pharmacology
Zunyi Medical University, Zhuhai, China

Received: 29-Dec-2022, Manuscript No. AATR-22-86936; Editor assigned: 03-Jan-2023, Pre QC No. AATR-23-86936(PQ); Reviewed: 14-Jan-2023, QC No. AATR-23-86936; Revised: 20-Jan-2023, Manuscript No. AATR-23-86936(R); Published: 28-Jan-2023, DOI:10.35841/aatr-7.1.133

Citation: Zhang Y. Symptoms of irritable bowel syndrome and ulcerative colitis in remission: A feasibility study. Am J Transl Res. 2023;7(1):133

Visit for more related articles at Journal of Translational Research


Irritable bowel syndrome, Management symptom, Inflammatory bowel disease.


Irritable bowel syndrome (IBS), which was marked by abdominal distension, a change in stool consistency, the perception of an incomplete evacuation, or pain that was relieved by faeces, was extremely common, affecting 11% of the general population worldwide. IBS can be divided into three categories: IBS-diarrhea (IBS-D), IBS-constipation (IBS-C) and IBS mixed with both (IBS-M). The precise physiopathology of IBS is still unknown as of this writing. At the time, the diagnosis of IBS was primarily made by ruling out any inflammatory, infectious, or malignant conditions. Low-quality empirical treatments, such as antispasmodics, probiotics, polyethylene glycol products, and faecal transplant, had been recommended to treat IBS symptoms. 3-Tricyclic antidepressants and mixed opioid agonists/antagonists (eluxadoline), two medications with effects on modulating visceral sensation and motility had been suggested to lessen the severity of IBS [1,2].

However, sedation, arrhythmia, and pancreatitis were frequently experienced in conjunction with the administration of these drugs. Finding alternative management to lessen IBS. In recent years, it has been discovered that patients with IBS have dysregulated endogenous melatonin. The enterochromaffin cells found throughout the digestive tract were a significant source of endogenous melatonin in addition to the pineal gland's secretion. By blocking nicotinic channels and interacting with Ca2+-activated K+ channels, endogenous melatonin stimulates and inhibits gut motility. In the animal model, melatonin supplementation at low doses sped up intestinal transit while supplementation at high doses slowed it. Additionally by increasing CCK release and turning on CCK1R and CCK2R [3].

The vagal nerve's afferent fibre may be stimulated by melatonin to modulate gastrointestinal motility. One of the main melatonin metabolites, 6-sulphatoxymelatonin, was measured in the urine of IBS patients to represent melatonin secretion. They found that the 6-sulphatoxymelatonin/ creatinine values were significantly lower in the IBS-C and IBS-D groups than in the healthy control group. Exogenous melatonin supplementation makes sense as a potential alternative IBS treatment. Exogenous melatonin supplements have emerged as one of the alternative treatments for IBS, based on the theory that patients with IBS have dysregulated endogenous melatonin levels. Saha et al. discovered in one preliminary randomised controlled trial (RCT) that exogenous melatonin supplementation significantly improved overall IBS severity and quality of life. Similar results were discovered in the other RCTs, which demonstrated a significant impact on IBS pain10 and an increase in the levels of salivary melatonin in IBS patients. These results weren't revealed in every RCT, though. To be more precise, an exogenous melatonin supplement reduced overall IBS severity in patients with IBS-C but not in those with IBS-D in later RCT conducted evidence from the meta-analysis could be summed up [4,5].


This study demonstrated that, by focusing on the selfmanagement process, both the pain self-management online education and nurse-led intervention were successful in reducing pain and enhancing quality of life in young adults with irritable bowel syndrome. The quality of life was improved more by the nurse-led intervention than by online education alone. In patients with IBS and co-morbid IBS/ IBD, dietary elimination can reduce symptoms and improve quality of life. Personalizing dietary interventions with digital technology can increase adherence. There is a need for randomised controlled trials.


  1. Lacy BE, Pimentel M, Brenner DM, et al. ACG clinical guideline: Management of irritable bowel syndrome. ACG. 2021;116(1):17-44.
  2. Indexed at, Google scholar, Cross ref

  3. Bubenik GA. Localization, physiological significance and possible clinical implication of gastrointestinal melatonin. Neurosignals. 2001;10(6):350-66.
  4. Indexed at, Google scholar, Cross ref

  5. Song GH, Leng PH, Gwee KA, et al. Melatonin improves abdominal pain in irritable bowel syndrome patients who have sleep disturbances: A randomised, double blind, placebo controlled study. Gut. 2005;54(10):1402-1407.
  6. Indexed at, Google scholar, Cross ref

  7. Duval S & Tweedie R. Trim and fill: a simple funnel‐plot-based method of testing and adjusting for publication bias in meta‐analysis. Biometrics. 2000;56(2):455-63.
  8. Indexed at, Google scholar, Cross ref

  9. Elsenbruch S, Harnish MJ, Orr WC. Subjective and objective sleep quality in irritable bowel syndrome. AJG. 1999; 94(9):2447-52.
  10. Indexed at, Google scholar, Cross ref

Get the App